Related Experiment Videos
Methotrexate in rheumatoid arthritis: when NSAIDs fail
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cleveland Clinic Journal of Medicine
|November 1, 1995
Summary
Methotrexate is a preferred treatment for rheumatoid arthritis unresponsive to NSAIDs. Low weekly doses offer effective disease management with an improved safety profile when patients are carefully monitored.
Area of Science:
- Rheumatology
- Pharmacology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are often insufficient for managing RA.
- Methotrexate has emerged as a primary therapeutic option for refractory RA.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose weekly methotrexate in rheumatoid arthritis patients.
- To assess methotrexate's role as a gold standard treatment for RA.
Main Methods:
- Review of clinical studies and patient data on methotrexate use in RA.
- Analysis of treatment outcomes and adverse events associated with low-dose methotrexate therapy.
Main Results:
- Methotrexate demonstrates significant efficacy in RA patients not responding to NSAIDs.
- Low weekly doses of methotrexate are associated with a favorable safety profile in carefully monitored patients.
- Original perceptions of methotrexate's safety have been revised based on current evidence.
Conclusions:
- Methotrexate is a highly effective and safe treatment for rheumatoid arthritis at low weekly doses.
- Diligent patient selection and monitoring are crucial for optimizing methotrexate therapy in RA.
- Methotrexate represents a cornerstone in the management of rheumatoid arthritis.